Warner, A., Abel, M. L., Slovin, S. F., Wei, X. X., Harshman, L. C., Kantoff, P. W., Aragon-Ching, J. B., Hankin, A., Williams, M., Mena, E., Lindenberg, M. L., Choyke, P. L., Arlen, P. M., Dahut, W. L., Figg, W. D., Donahue, R. N., Schlom, J., Gulley, J. L., Karzai, F., Madan, R. A. (2026). Immunotherapy in intermediate-risk biochemically recurrent prostate cancer (BCR): The National Cancer Institute experience.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2026.44.7_suppl.170